These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21308371)

  • 1. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres.
    Haug AR; Heinemann V; Bruns CJ; Hoffmann R; Jakobs T; Bartenstein P; Hacker M
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1037-45. PubMed ID: 21308371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioembolization with (90)Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors.
    Soydal C; Kucuk ON; Bilgic S; Ibis E
    Ann Nucl Med; 2016 Jan; 30(1):29-34. PubMed ID: 26370716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres.
    Ulrich G; Dudeck O; Furth C; Ruf J; Grosser OS; Adolf D; Stiebler M; Ricke J; Amthauer H
    J Nucl Med; 2013 Apr; 54(4):516-22. PubMed ID: 23447653
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Nezami N; Kokabi N; Camacho JC; Schuster DM; Xing M; Kim HS
    Nucl Med Biol; 2018 Apr; 59():22-28. PubMed ID: 29448165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization.
    Filippi L; Di Costanzo GG; Tortora R; Pelle G; Saltarelli A; Marino Marsilia G; Cianni R; Schillaci O; Bagni O
    Nucl Med Commun; 2020 Jan; 41(1):78-86. PubMed ID: 31800510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET response criteria for solid tumors predict survival at three months after intra-arterial resin-based 90Yttrium radioembolization therapy for unresectable intrahepatic cholangiocarcinoma.
    Camacho JC; Kokabi N; Xing M; Schuster DM; Kim HS
    Clin Nucl Med; 2014 Nov; 39(11):944-50. PubMed ID: 25140563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.
    Sabet A; Meyer C; Aouf A; Sabet A; Ghamari S; Pieper CC; Mayer K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):370-6. PubMed ID: 25351506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma.
    Filippi L; Pelle G; Cianni R; Scopinaro F; Bagni O
    Nucl Med Biol; 2015 Jan; 42(1):59-64. PubMed ID: 25213104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours.
    Meyer C; Pieper CC; Ezziddin S; Wilhelm KE; Schild HH; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):231-7. PubMed ID: 24030669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
    Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
    Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
    Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
    J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
    Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.
    Sabet A; Ahmadzadehfar H; Bruhman J; Sabet A; Meyer C; Wasmuth JC; Pieper CC; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):39-45. PubMed ID: 24777354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.
    Levillain H; Duran Derijckere I; Ameye L; Guiot T; Braat A; Meyer C; Vanderlinden B; Reynaert N; Hendlisz A; Lam M; Deroose CM; Ahmadzadehfar H; Flamen P
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2270-2279. PubMed ID: 31324943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolization with
    Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.